PositoAI/ US/ Aytu BioPharma, Inc.

Aytu BioPharma, Inc.

NasdaqCM: AYTU · Healthcare

Positivity Index

#3,779 / 6,775

Global

#1,701 / 4,000

United States

Positivity Score

20,282

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Aytu BioPharma, Inc. — Overview & Financial Snapshot

Aytu BioPharma, Inc. (NasdaqCM: AYTU) is a Healthcare company, ranked #3,779 of 6,775 companies globally and #1,701 of 4,000 in United States on PositoAI, with a Positivity Score of 20,282. Its market capitalisation is ₹203.09 Cr ($21.52M), P/E ratio is -1.7 and P/B ratio is 0.61. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

P/B Ratio 0.61

P/E Ratio -1.7

D/E Ratio 0.51

ROE -52.55%

Owes vs Owns ? 0.66× Moderate $0.66 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-109.49$-1.16

Forward EPS ₹14.63$0.16

Beta 0.18

Market Cap ₹203.09 Cr$21.52M

What these numbers mean →

What does Aytu BioPharma, Inc. do?

What is Aytu BioPharma, Inc.'s P/E and P/B ratio?

Aytu BioPharma, Inc. has a P/E ratio of -1.7 and a P/B ratio of 0.61.

What is Aytu BioPharma, Inc.'s debt-to-equity ratio?

Aytu BioPharma, Inc. has a debt-to-equity ratio of 0.51.

How much does Aytu BioPharma, Inc. owe compared with what it owns?

Aytu BioPharma, Inc. owes $0.66 for every $1 it owns (balance sheet Jun 2026), which is moderate.

What is Aytu BioPharma, Inc.'s Positivity rank?

Aytu BioPharma, Inc. is ranked #3,779 of 6,775 companies globally and #1,701 of 4,000 in United States on PositoAI, with a Positivity Score of 20,282.

Does Aytu BioPharma, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Aytu BioPharma, Inc..

Where can I read the latest news about Aytu BioPharma, Inc.?

Recent headlines about Aytu BioPharma, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Aytu BioPharma, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Aytu BioPharma, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.